AstraZeneca PLC (ETR:ZEG)
Germany
· Delayed Price · Currency is EUR 155.75
+1.00 (0.65%)
At close: Dec 5, 2025
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B USD in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
4.87
Revenue / Employee
$616.41K
Employees
94,300
Market Cap
241.39B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.27B |
| Siemens Healthineers AG | 23.38B |
| Bayer Aktiengesellschaft | 45.87B |
| Fresenius SE & Co. KGaA | 22.45B |
| Sartorius Aktiengesellschaft | 3.52B |
| Fresenius Medical Care AG | 19.64B |
| Carl Zeiss Meditec AG | 2.18B |
| Fielmann Group AG | 2.42B |
AstraZeneca News
- 1 day ago - Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement - Business Wire
- 1 day ago - FDA Streamlines Clinical Study Requirements, Impacting AstraZeneca (AZN) - GuruFocus
- 1 day ago - AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval - GuruFocus
- 1 day ago - AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025 - GuruFocus
- 1 day ago - AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - Wallstreet:Online
- 1 day ago - AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - Business Wire
- 2 days ago - AstraZeneca Shares Dip 0.7% Amid Patent Cliff Fears, But Pipeline Strength Fuels Long-Term Optimism - ABC Money
- 2 days ago - AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Benzinga